Voyager Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Voyager hired Amy Quinlan as Vice President, Finance effective December 17, 2024, with base salary $345,000, 30% bonus target, 50,000 stock options, and 25,000 RSUs. Separately, the company amended its Certificate of Incorporation on June 9, 2026, doubling authorized common shares from 120M to 240M (total authorized capital from 125M to 245M shares), maintaining 5M authorized preferred shares.
Why this rating
Routine executive hire at VP level; cap authorization increase is defensive/administrative. Both immaterial relative to $144M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.